HK1120209A1 - Use of fused heterocyclic compounds as scce inhibitors - Google Patents

Use of fused heterocyclic compounds as scce inhibitors

Info

Publication number
HK1120209A1
HK1120209A1 HK08110652.0A HK08110652A HK1120209A1 HK 1120209 A1 HK1120209 A1 HK 1120209A1 HK 08110652 A HK08110652 A HK 08110652A HK 1120209 A1 HK1120209 A1 HK 1120209A1
Authority
HK
Hong Kong
Prior art keywords
heterocyclic compounds
fused heterocyclic
scce
inhibitors
scce inhibitors
Prior art date
Application number
HK08110652.0A
Other languages
English (en)
Inventor
M Linschoten
Original Assignee
Arexis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arexis Ab filed Critical Arexis Ab
Publication of HK1120209A1 publication Critical patent/HK1120209A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK08110652.0A 2003-06-06 2008-09-25 Use of fused heterocyclic compounds as scce inhibitors HK1120209A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300840 2003-06-06
DKPA200300843 2003-06-06
DKPA200300844 2003-06-06
DKPA200300842 2003-06-06

Publications (1)

Publication Number Publication Date
HK1120209A1 true HK1120209A1 (en) 2009-03-27

Family

ID=33514772

Family Applications (2)

Application Number Title Priority Date Filing Date
HK06112281.7A HK1091731A1 (en) 2003-06-06 2006-11-08 Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
HK08110652.0A HK1120209A1 (en) 2003-06-06 2008-09-25 Use of fused heterocyclic compounds as scce inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK06112281.7A HK1091731A1 (en) 2003-06-06 2006-11-08 Pharmaceutical use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer

Country Status (18)

Country Link
US (1) US7872052B2 (xx)
EP (1) EP1631295B1 (xx)
JP (1) JP5044214B2 (xx)
KR (2) KR101099409B1 (xx)
CN (1) CN101152185B (xx)
AT (1) ATE459359T1 (xx)
CA (1) CA2525383C (xx)
CY (1) CY1110084T1 (xx)
DE (1) DE602004025803D1 (xx)
DK (1) DK1631295T3 (xx)
ES (1) ES2341545T3 (xx)
HK (2) HK1091731A1 (xx)
NO (1) NO20060091L (xx)
NZ (1) NZ543636A (xx)
PL (1) PL1631295T3 (xx)
PT (1) PT1631295E (xx)
SI (1) SI1631295T1 (xx)
WO (1) WO2004108139A2 (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US7879846B2 (en) 2006-09-21 2011-02-01 Kyorin Pharmaceutical Co.., Ltd. Serine hydrolase inhibitors
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2183270B1 (en) * 2007-08-17 2014-12-17 Novartis AG Use of cyclic depsipeptides to inhibit kallikrein 7
PT2183273T (pt) 2007-08-17 2017-05-22 Novartis Ag Depsipéptidos cíclicos
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (xx) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх Похідні 1-гетероцикліл-1,5-дигідропіразоло$3,4-d]піримідин-4-ону та їх застосування як модулятори pde9a$производные 1-гетероциклил-1,5-дигидропиразоло$3,4-d] пиримидин-4-она и их применение в качестве модуляторов pde9a
EA201100446A1 (ru) 2008-09-08 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Пиразолопиримидины и их применение для лечения нарушений цнс
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010101302A1 (en) * 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
MY156377A (en) 2009-03-31 2016-02-15 Boehringer Ingelheim Int 1-heterocycl-1, 5-dihydro-pyrazolo [3 , 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
AR086168A1 (es) 2011-04-20 2013-11-27 Novartis Ag Procesos para la elaboracion de depsipeptidos macrociclicos e intermediarios
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
CA2867467A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HUE052990T2 (hu) * 2014-01-23 2021-05-28 Sixera Pharma Ab Új kallikrein 7 gátlók
PT3097085T (pt) * 2014-01-23 2020-10-08 Sixera Pharma Ab Derivados de benzoxazinona para tratamento de doenças de pele
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201705088VA (en) 2014-12-23 2017-07-28 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en) * 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN108421034A (zh) * 2018-04-24 2018-08-21 济南磐升生物技术有限公司 激肽释放酶7在皮肤创伤愈合中的应用
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
JP2021523118A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の塩
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220091488A (ko) 2019-10-01 2022-06-30 몰레큘러 스킨 테라퓨틱스, 인코포레이티드 Klk5/7 이중 억제제로서의 벤족사지논 화합물
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
EP4346761A1 (en) 2021-06-01 2024-04-10 Sixera Pharma AB Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023250321A1 (en) * 2022-06-21 2023-12-28 Dana-Farber Cancer Institute, Inc. Fused bicyclic egfr inhibitors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
FR2121341A1 (en) * 1971-01-04 1972-08-25 Ferlux 2-substd-3,1-benzoxazin-4-ones - antiinflammatories, analgesics sedatives and diuretics
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
JPS5576868A (en) 1978-12-01 1980-06-10 Hisamitsu Pharmaceut Co Inc Novel 3,1-bezoxazine derivative
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
AU634994B2 (en) * 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
AU635403B2 (en) * 1990-02-15 1993-03-18 Teijin Limited 4h-3,1-benzoxazin-4-one compound and elastase inhibitor composition containing the same
JPH07316056A (ja) * 1990-02-15 1995-12-05 Teijin Ltd エラスターゼ阻害用医薬組成物
JPH05509302A (ja) * 1990-06-20 1993-12-22 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
AU1375000A (en) * 1998-11-26 2000-06-13 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2001017564A2 (en) * 1999-09-10 2001-03-15 The Procter & Gamble Company Enzyme inhibitors
ATE515940T1 (de) 2001-02-09 2011-07-15 Torbjoern Egelrud Scce transgene mäuse und deren verwendung als modell für menschliche krankheiten
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
GB2410025B (en) * 2002-10-03 2007-03-28 Inst Med Molecular Design Inc Quinazolin-4-one derivatives
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS

Also Published As

Publication number Publication date
JP5044214B2 (ja) 2012-10-10
NZ543636A (en) 2009-07-31
DK1631295T3 (da) 2010-06-21
CN101152185B (zh) 2010-12-08
HK1091731A1 (en) 2007-01-26
ES2341545T3 (es) 2010-06-22
CN101152185A (zh) 2008-04-02
KR101099409B1 (ko) 2011-12-27
JP2006526581A (ja) 2006-11-24
KR20060008331A (ko) 2006-01-26
EP1631295B1 (en) 2010-03-03
SI1631295T1 (sl) 2010-06-30
CA2525383C (en) 2012-03-06
PL1631295T3 (pl) 2010-09-30
WO2004108139A2 (en) 2004-12-16
WO2004108139A8 (en) 2005-04-28
AU2004244704A1 (en) 2004-12-16
DE602004025803D1 (de) 2010-04-15
CA2525383A1 (en) 2004-12-16
CY1110084T1 (el) 2015-01-14
US20060258651A1 (en) 2006-11-16
PT1631295E (pt) 2010-05-24
US7872052B2 (en) 2011-01-18
NO20060091L (no) 2006-03-06
KR101205257B1 (ko) 2012-11-27
KR20110120960A (ko) 2011-11-04
WO2004108139A3 (en) 2005-03-10
EP1631295A2 (en) 2006-03-08
ATE459359T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
HK1120209A1 (en) Use of fused heterocyclic compounds as scce inhibitors
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TNSN08227A1 (en) [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
ATE541571T1 (de) Diarylhydantoin-verbindung
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
RS20050363A (xx) Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
UA85559C2 (xx) Сполуки амінобензофенону$соединения аминобензофенона
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
UA90698C2 (xx) Триазолзаміщені амінобензофенонові сполуки$триазолзамещеные аминобензофеноновые соединения
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
WO2007120333A3 (en) Tetracyclic kinase inhibitors
UA85087C2 (xx) Моноциклічні гетероцикли як інгібітори кінази$моноциклические гетероциклы - ингибиторы киназы
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
DE50311665D1 (de) Guanidinophenylalanin-verbindungen als urokinase-inhibitoren
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
DK1687301T3 (da) Thiaepothilone til behandling af kræftsygdomme
UA96570C2 (ru) Лиганды н3-рецептора гистамина и их терапевтические применения
EA201791835A2 (ru) Ингибиторы протеасом

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170607